Tick-borne encephalitis vaccine - Pfizer

Drug Profile

Tick-borne encephalitis vaccine - Pfizer

Alternative Names: FSME-IMMUN Junior; FSME-IMMUN NEW; FSME-IMMUNE; TicoVac; TicoVac Junior

Latest Information Update: 06 Aug 2014

Price : $50

At a glance

  • Originator Hyland Immuno
  • Developer Hyland Immuno; Pfizer
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Encephalitis virus infections

Most Recent Events

  • 30 Jul 2014 Pfizer signs a definitive agreement to acquire tick-borne encephalitis vaccine from Baxter
  • 17 Feb 2004 A clinical study has been added to the adverse events and Viral Infections immunogenicity sections
  • 21 Jun 2002 New formulation registered for Encephalitis virus infections in Germany (injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top